Compare Inovio Pharmaceuticals Inc (INO) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Invesco NASDAQ 100 ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 1010.8× Inovio Pharmaceuticals Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| INO | QQQM | |
|---|---|---|
Market Cap | $112.19M | $113.40B |
Volume | 3,201,278 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $2.65 | $312.76 |
52-Week Low | $0.66 | $229.87 |
Typical Hold Time | 43 Days | 54 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
QQQM trades at $307.85, down 1.33% today, while maintaining a bullish technical outlook with strong moving average support. The Invesco NASDAQ 100 ETF continues to benefit from institutional accumulation, with QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show the ETF trading near key resistance at $309, with support established at $305 and $303 levels. The fund's 0.15% expense ratio provides a cost advantage over similar NASDAQ-100 tracking products.
QQQM offers efficient exposure to NASDAQ-100 growth stocks with lower fees, though concentration in technology sectors presents volatility risks. Institutional buying signals confidence in the ETF's long-term prospects despite recent market fluctuations. Investors should monitor technology sector performance and interest rate sensitivity as key drivers of future returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
